First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]

Table 3 Change from baseline and treatment differences in WOMAC™ total and subscale scores at study end

	WOMAC™ total score	WOMAC™ pain subscale score	WOMAC™ DPDA subscale score^a	WOMAC™ stiffness subscale score
Change from baseline at study end (mean ± SD)
Lumiracoxib 400 mg daily (n = 144)	-21.3 ± 19.9	-4.4 ± 4.4	-15.4 ± 14.6	-1.5 ± 1.9
Celecoxib 200 mg twice daily (n = 145)	-17.6 ± 14.2	-4.0 ± 3.3	-12.3 ± 10.5	-1.3 ± 1.8
Placebo (n = 75)	-12.5 ± 13.4	-2.7 ± 3.2	-9.0 ± 9.8	-0.8 ± 1.5
Estimated treatment differences at study end (least square means [95% CI])
Lumiracoxib versus placebo	-8.9 (-13.30 to -4.56)***	-1.8 (-2.77 to -0.83)***	-6.4 (-9.62 to -3.23)***	-0.7 (-1.14 to -0.31)***
Celecoxib versus placebo	-4.8 (-9.15 to -0.44)*	-1.1 (-2.02 to -0.10)*	-3.1(-6.30 to +0.07)	-0.6 (-1.00 to -0.18)**
Lumiracoxib versus celecoxib	-4.1 (-7.76 to -0.51)*	-0.7 (-1.54 to +0.06)	-3.3 (-5.96 to -0.66)*	-0.1 (-0.47 to +0.21)

^aData missing for one patient in each of the lumiracoxib and celecoxib treatment groups. *P < 0.05, **P < 0.01, ***P = 0.001. CI, confidence interval; DPDA, difficulty in performing daily activities; SD, standard deviation; WOMAC™ = Western Ontario and McMaster Universities Osteoarthritis Index.

ISSN: 1478-6362